Skip to main content
Top
Published in: BMC Women's Health 1/2015

Open Access 01-12-2015 | Research article

The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland

Authors: Anni Virtanen, Ahti Anttila, Pekka Nieminen

Published in: BMC Women's Health | Issue 1/2015

Login to get access

Abstract

Background

Offering self-sampling to non-attendees of cervical screening increases screening attendance.

Methods

We used observations from two Finnish studies on the use of self-sampling among the non-attendees to estimate in a hypothetical screening population of 100,000 women the possible costs per extra screened woman and costs per extra detected and treated CIN2+ with three intervention strategies; 1) a primary invitation and a reminder letter, 2) a primary invitation and a mailed self-sampling kit and 3) two invitation letters and a self-sampling kit. The program costs were derived from actual performance and costs in the original studies and a national estimate on management costs of HPV related diseases.

Results

The price per extra participant and price per detected and treated CIN2+ lesion was lower with a reminder letter than by self-sampling as a first reminder. When self-sampling was used as a second reminder with a low sampler price and a triage Pap-smear as a follow-up test for HPV-positive women instead of direct colposcopy referral, the eradication of a CIN2+ lesion by self-sampling was not more expensive than in routine screening, and the addition of two reminders to the invitation protocol did not increase the price of an treated CIN2+ lesion in the entire screened population.

Conclusions

As a first reminder, a reminder letter is most likely a better choice. As second reminder, the higher costs of self-sampling might be compensated by the higher prevalence of CIN2+ in the originally non-attending population.
Literature
5.
go back to reference Pritchard DA, Straton JA, Hyndman J. Cervical screening in general practice. Aust J Public Health. 1995;19:167–72.CrossRefPubMed Pritchard DA, Straton JA, Hyndman J. Cervical screening in general practice. Aust J Public Health. 1995;19:167–72.CrossRefPubMed
6.
go back to reference Segnan N, Senore C, Giordano L, Ponti A, Ronco G. Promoting participation in a population screening program for breast and cervical cancer: a randomized trial of different invitation strategies. Tumori. 1998;84:348–53.PubMed Segnan N, Senore C, Giordano L, Ponti A, Ronco G. Promoting participation in a population screening program for breast and cervical cancer: a randomized trial of different invitation strategies. Tumori. 1998;84:348–53.PubMed
7.
go back to reference Hermens RP, Hak E, Hulscher ME, Mulder J, Tacken MA, Braspenning JC, et al. Improving population-based cervical cancer screening in general practice: effects of a national strategy. Int J Qual Health Care. 1999;11:193–200.CrossRefPubMed Hermens RP, Hak E, Hulscher ME, Mulder J, Tacken MA, Braspenning JC, et al. Improving population-based cervical cancer screening in general practice: effects of a national strategy. Int J Qual Health Care. 1999;11:193–200.CrossRefPubMed
8.
go back to reference Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J. The determinants of screening uptake and interventions for increasing uptake: a systematic review. Health Technol Assess. 2000;4:1–133. Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J. The determinants of screening uptake and interventions for increasing uptake: a systematic review. Health Technol Assess. 2000;4:1–133.
9.
go back to reference Eaker S, Adami HO, Granath F, Wilander E, Sparen P. A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:346–54.PubMed Eaker S, Adami HO, Granath F, Wilander E, Sparen P. A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:346–54.PubMed
10.
go back to reference Morrell S, Taylor R, Zeckendorf S, Niciak A, Wain G, Ross J. How much does a reminder letter increase cervical screening among under-screened women in NSW? Aust N Z J Public Health. 2005;29:78–84.CrossRefPubMed Morrell S, Taylor R, Zeckendorf S, Niciak A, Wain G, Ross J. How much does a reminder letter increase cervical screening among under-screened women in NSW? Aust N Z J Public Health. 2005;29:78–84.CrossRefPubMed
11.
go back to reference Everett T, Bryant A, Griffin MF, Martin-Hirsch PP, Forbes CA, Jepson RG. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev 2011:CD002834. doi:10.1002/14651858.CD002834.pub2. Everett T, Bryant A, Griffin MF, Martin-Hirsch PP, Forbes CA, Jepson RG. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev 2011:CD002834. doi:10.​1002/​14651858.​CD002834.​pub2.
12.
13.
go back to reference Virtanen A, Anttila A, Luostarinen T, Nieminen P. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int J Cancer. 2011;128:2681–7. doi:10.1002/ijc.25581.CrossRefPubMed Virtanen A, Anttila A, Luostarinen T, Nieminen P. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int J Cancer. 2011;128:2681–7. doi:10.​1002/​ijc.​25581.CrossRefPubMed
14.
go back to reference Virtanen A, Anttila A, Luostarinen T, Malila N, Nieminen P. Improving cervical cancer screening attendance in Finland. Int J Cancer 2015:136(6):E677-84. doi:10.1002/ijc.29176 Virtanen A, Anttila A, Luostarinen T, Malila N, Nieminen P. Improving cervical cancer screening attendance in Finland. Int J Cancer 2015:136(6):E677-84. doi:10.​1002/​ijc.​29176
15.
go back to reference Broberg G, Jonasson JM, Ellis J, Gyrd-Hansen D, Anjemark B, Glantz A, et al. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial. Int J Cancer. 2013;133:164–71. doi:10.1002/ijc.27985.CrossRefPubMed Broberg G, Jonasson JM, Ellis J, Gyrd-Hansen D, Anjemark B, Glantz A, et al. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial. Int J Cancer. 2013;133:164–71. doi:10.​1002/​ijc.​27985.CrossRefPubMed
18.
go back to reference Gök M, Heideman DAM, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JWM, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ. 2010;340:c1040. doi:10.1136/bmj.c1040.CrossRefPubMedPubMedCentral Gök M, Heideman DAM, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JWM, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ. 2010;340:c1040. doi:10.​1136/​bmj.​c1040.CrossRefPubMedPubMedCentral
20.
go back to reference Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Le Retraite L, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013;133:2681–7. doi:10.1002/ijc.28283.PubMed Sancho-Garnier H, Tamalet C, Halfon P, Leandri FX, Le Retraite L, Djoufelkit K, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013;133:2681–7. doi:10.​1002/​ijc.​28283.PubMed
21.
go back to reference Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer. 2011;104:248–54. doi:10.1038/sj.bjc.6606040.CrossRefPubMed Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer. 2011;104:248–54. doi:10.​1038/​sj.​bjc.​6606040.CrossRefPubMed
22.
go back to reference Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd M-L, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2014;134:2223–30. doi:10.1002/ijc.28545.CrossRefPubMed Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd M-L, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2014;134:2223–30. doi:10.​1002/​ijc.​28545.CrossRefPubMed
23.
go back to reference Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer. 2000;36:2209–14.CrossRefPubMed Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer. 2000;36:2209–14.CrossRefPubMed
24.
go back to reference Salo H, Nieminen P, Kilpi T, Auranen K, Leino T, Vänskä S, et al. Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland. Int J Cancer. 2014;135:204–13. doi:10.1002/ijc.28646.CrossRefPubMed Salo H, Nieminen P, Kilpi T, Auranen K, Leino T, Vänskä S, et al. Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland. Int J Cancer. 2014;135:204–13. doi:10.​1002/​ijc.​28646.CrossRefPubMed
25.
go back to reference Salo H, Leino T, Kilpi T, Auranen K, Tiihonen P, Lehtinen M, et al. The burden and costs of prevention and management of genital disease caused by HPV in women: A population-based registry study in Finland. Int J Cancer. 2013;133:1459–69. doi:10.1002/ijc.28145.CrossRefPubMed Salo H, Leino T, Kilpi T, Auranen K, Tiihonen P, Lehtinen M, et al. The burden and costs of prevention and management of genital disease caused by HPV in women: A population-based registry study in Finland. Int J Cancer. 2013;133:1459–69. doi:10.​1002/​ijc.​28145.CrossRefPubMed
26.
go back to reference Haguenoer K, Sengchanh S, Gaudy-Graffin C, Boyard J, Fontenay R, Marret H, et al. Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer 2014:1–10. doi:10.1038/bjc.2014.510 Haguenoer K, Sengchanh S, Gaudy-Graffin C, Boyard J, Fontenay R, Marret H, et al. Vaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer 2014:1–10. doi:10.​1038/​bjc.​2014.​510
28.
go back to reference Rozemeijer K, de Kok IMCM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, et al. Offering self-sampling to non-attendees of organized primary HPV screening: When do harms outweigh the benefits? Cancer Epidemiol Biomarkers Prev 2014. doi:10.1158/1055-9965.EPI-14-0998 Rozemeijer K, de Kok IMCM, Naber SK, van Kemenade FJ, Penning C, van Rosmalen J, et al. Offering self-sampling to non-attendees of organized primary HPV screening: When do harms outweigh the benefits? Cancer Epidemiol Biomarkers Prev 2014. doi:10.​1158/​1055-9965.​EPI-14-0998
29.
go back to reference Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer. 2007;120:1505–10.CrossRefPubMed Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer. 2007;120:1505–10.CrossRefPubMed
31.
go back to reference Verhoef VMJ, Bosgraaf RP, Van Kemenade FJ, Rozendaal L, Heideman DA M, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014;15:315–22.CrossRefPubMed Verhoef VMJ, Bosgraaf RP, Van Kemenade FJ, Rozendaal L, Heideman DA M, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014;15:315–22.CrossRefPubMed
32.
Metadata
Title
The costs of offering HPV-testing on self-taken samples to non-attendees of cervical screening in Finland
Authors
Anni Virtanen
Ahti Anttila
Pekka Nieminen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2015
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-015-0261-7

Other articles of this Issue 1/2015

BMC Women's Health 1/2015 Go to the issue